New study brings new insights into the correlation of physical activity and dietary habits with weight gain in people who carry different variations of the FTO gene—aka ‘the fat gene.’
Direct to consumer testing can potentially be quite dangerous without appropriate regulations and support to fully understand the implications of the information a consumer receives.
23andMe has received the first-ever FDA authorisation for a direct-to-consumer genetic test for cancer risk for its BRCA1 and BRCA2 report.
Dame Sally Davies insists that learning more about a patient’s genetic makeup will lead to a better and more cost-effective approach, that will ultimately spare resources in the system.
Researchers are developing a test for Zika that uses saliva to identify diagnostic markers of the virus much more quickly than current commercial tests can.
23andMe is updating its methods on its $99 genealogy test to trace ancestry back to 120 more populations, for a total of 151.
“How Can We Anticipate and Respond to Technologies and Information That is Rapidly Changing?” – Josephine Johnston
Josephine Johnston is an expert on the ethical, legal and policy implications of biomedical technologies, particularly as used in human reproduction, psychiatry, genetics, and neuroscience.
There are wide differences in BRCA testing protocols at labs around the world. A new article surveyed 86 laboratories about their BRCA testing practices and found that all the labs differed widely in their approach.
The number of people who have had their DNA analyzed with direct-to-consumer tests more than doubled during 2017, and now exceeds 12 million according to industry estimates.
Scientists have been able to show that tiny autonomous bots have the potential to function as intelligent delivery vehicles to cure cancer in mice.
Cervical cancer is the second leading cause of cancer-related death for women between the ages of 20 and 39, but thanks to an effective HPV vaccine some cases can now be prevented.
Reading the whole genetic blueprint of a fetus long before birth could become a routine procedure thanks to a new blood test.
European drugmaker and the world’s biggest insulin maker, Novo Nordisk, wants to prove it can transform the diabetes market with a pill.